Search

everythinglearnresearchcommunity

for

Search:↓

Over half of the participants in a Saudi Arabian survey experienced hair loss after COVID-19, affecting women and younger people more, with a small percentage feeling a severe impact on their lives.

Over half of young people in Saudi Arabia experience early gray hair, linked to factors like smoking, stress, and family history.

Nearly half of the classification tools in the National Institute of Health and Clinical Excellence's Clinical Knowledge Summaries might not effectively guide management for general practitioners.

Over half of the dog skin disorders discussed have known gene variants, enabling genetic testing for diagnosis and responsible breeding.

Over half of the diabetes patients had skin issues, with fungal infections being most common.

Long COVID affects over half of COVID-19 survivors, causing a range of symptoms like fatigue and neurological issues, with no specific treatment yet.

More than half of patients who had acromegaly surgery experienced hair loss, with varying degrees of recovery.

More than half of the women with PCOS in Southern India had Metabolic Syndrome, with large waist circumference being the most common feature.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.

More than half of the Thai women with PCOS had polycystic ovarian morphology.

More than half of the young women checked had PCOS, which was linked to inactive lifestyles and poor diets.

Up to half of people experience itchy scalp, often due to skin conditions like seborrheic dermatitis or psoriasis, and treatments vary based on the specific cause.

Up to half of women by age 50 experience significant hair loss, with various types and treatments available.

Up to half of adult women may experience hair loss, and doctors should use medical history, exams, and tests to find the cause and treat it.

Children receive less than half of recommended health care, and routine hormonal testing for female-pattern hair loss is unnecessary without other androgen excess symptoms.

Bimatoprost helped eyelash growth in nearly half of the patients with a type of eyelash hair loss.

Azathioprine caused side effects in over half of the Korean pediatric inflammatory bowel disease patients, requiring close monitoring.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Scalp cooling prevented hair loss in half of the patients, despite significant side effects.

PUVA treatment led to significant hair regrowth in over half of the patients with alopecia areata totalis and universalis.

Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.

Scalp cooling therapy helped over 80% of women keep at least half their hair during chemotherapy.

Using a microscope during hair transplants cuts damage to follicles in half and could improve hair growth.

Pregnant women often experience skin and hair changes, with over half getting stretch marks and pigment changes, and should be cautious with cosmetic procedures due to potential risks.

Melanoma survivors are more likely to use sunscreen and seek shade than others, but less than half often use sunscreen and avoid the sun, and some still use tanning beds.

Breast implants are linked to autoimmune symptoms, with over half of patients feeling better after removal, but the exact cause is unclear and may involve bacterial biofilm.

The document concludes that fexofenadine reduces inflammation in chronic hives, cholestyramine helps half of pregnant women with itchy rashes, and relaxing incisions are a good alternative in facial surgery for the elderly.

Using more minoxidil solution can lead to better hair growth, but people often use only half the recommended amount. Education and motivation can improve results.

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.